IGC Pharma, Inc.
Close on Oct 19, 2026
- Market cap
- $24.28M
- P/E (TTM)
- –
- Dividend yield
- –
About IGC Pharma
Pharmaceutical Preparations, SIC 2834
IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing therapies to treat and diagnose central nervous system disorders, primarily Alzheimer’s disease. The company operates in a single reportable segment, Life Sciences, having previously realigned away from its legacy Infrastructure activities. Its product pipeline centers on innovative drug candidates targeting neurodegenerative conditions, notably its lead candidate IGC-AD1, which is undergoing clinical evaluation for agitation associated with Alzheimer’s dementia. Additionally, the company advances preclinical therapeutic candidates targeting amyloid-beta plaque formation and metabolic disorders, while applying artificial intelligence and machine learning models to identify early diagnostic markers and optimize clinical trials.
The company is incorporated in Maryland and maintains its principal executive offices in Potomac, Maryland. It conducts clinical and developmental activities across North America, including clinical trial sites in the United States and Canada, and harmonizes longitudinal and clinical research databases representing international participants across the Americas and Asia.
Summary of the business section of IGC Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IGC Pharma, Inc.
- Founded
- 2005
- Headquarters
- Potomac, MD
- Address
- 10224 Falls Road 20854
- Phone
- (301) 529-4996
- Employees
- 67, Mar 31, 2024
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Maryland
- Fiscal year ends
- December 31
- Auditor
- Manohar Chowdhry & Associates, Chennai, India
Stock & identifiers
- Ticker
- IGC
- Exchange
- NYSE
- IPO date
- Mar 7, 2006
- Shares outstanding
- 103M, Aug 5, 2026
- Public float
- $18.46M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-1062 reverse, Oct 16, 2018; 1-for-10 reverse, Jul 16, 2013; 1-for-10 reverse, Apr 19, 2013
- SEC CIK
- 1326205
- CUSIP
- 45408X308
- ISIN
- US45408X3089
- LEI
- 529900TIWO8H06FQC983
- EIN
- 20-2760393
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ram Mukunda | CEO, Director | 7,652,982 |
| Claudia Grimaldi | PFO, Director | 3,271,092 |
| Richard K. Prins | Director | 1,541,251 |
| James P. Moran | Director | 2,128,137 |
| Terry L. Lierman | Director | 29,411 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Ram Mukunda | $568.00K | -$203.00K | $259.00K | $70000 | – |
| FY2024 Mr. Ram Mukunda | $1.82M | $2.70M | $717.00K | $118000 | – |
| FY2023 Mr. Ram Mukunda | $1.01M | -$1.45M | $320.00K | $33000 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 31, 2024, we employed a team of approximately 67 full-time employees in our two segments.”
Corporate history
Events identified from SEC filings